(RTTNews) – Today’s Daily Dose brings you news about the first rolling review of a COVID-19 vaccine in the EU, reverse merger of privately held Chinook Therapeutics with Aduro, Enlivex Therapeutics’ positive top-line results of an investigator-initiated clinical trial of Allocetra in COVID-19 patients in severe/critical condition, FDA lifting the clinical hold on Solid Biosciences’ IGNITE DMD trial, and Vaccibody’s deal with Roche to develop neoantigen cancer vaccines.

Read on…

1. EU begins First Rolling Review of COVID-19 vaccine

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has started the ‘rolling review’ of AZD1222, the COVID-19 vaccine candidate, being developed by AstraZeneca plc (AZN) in collaboration with the University of Oxford.

This marks the first ‘rolling review’ of a COVID-19 vaccine, and the data being reviewed by the committee comes from laboratory studies (non-clinical data). The CHMP decided to start the rolling review of the AZD1222 vaccine based on preliminary results from non-clinical and early clinical studies which suggest that the vaccine triggers the production of antibodies and T cells (cells of the immune system, the body’s natural defense) that target the virus.

AZD1222 advanced into phase III testing in the U.S. in late August. The vaccine candidate is being tested in phase II/III trials in the U.K. and Brazil and in phase I/II trial in South Africa.

Early this month, AstraZeneca paused all the AZD1222 vaccine trials following a single event of an unexplained illness, which is believed to be transverse myelitis that occurred in the UK phase III trial. While the trials of the vaccine candidate in the UK and other countries have resumed, the trial continues to remain on hold in the U.S. as regulators have asked the company to furnish further data over its safety.

Gilead Sciences’ antiviral Veklury (remdesivir), which secured

a close up of a piece of paper

© Provided by Zee Business

Health Insurance Plans: From 1st October 2020, a lot of changes related to one’s personal finance is changing. These changes will have a direct impact on one’s pocket and regular expenses. Health insurance plans are one such area that is going to change completely from next month i.e. from 1st October 2020. From this date insurance companies won’t be able to reject insurance claims with ease. 

If a health insurance plan holder has paid a policy premium for eight years, then the insurance company can’t reject the insurance claim in the wake of a loophole in the claim. Now a health insurance plan will cover the maximum number of diseases, however, it will lead to a rise in the health insurance policy premium.

See Zee Business Live TV streaming below:

Major changes from 1st October in the insurance sector

1] Coverage of the number of diseases will get increased;

2] Major diseases outside the health insurance policy will be the same for all insurance companies;

3] Major diseases outside health insurance plan will come down to 17 only;

4] If the major diseases outside plan is 10, then health insurance premium will come down as well;

5] If the major diseases outside plan is 30, then health insurance premium for such plans will go up;

6] In new health insurance products, insurance premium is expected to go northward from 5 per cent to 20 per cent;

7] Psychiatric, genetic and neuro diseases will also get covered in health insurance plans;

8] Neuro disorder, oral chemotherapy, robotic surgery and stem cell therapy will also get covered under health insurance plans.

Terms and conditions for pre-exit

1] A disease pointed out by the doctor before 48 months will be considered for pre-existing under the health insurance plan;

Mark J. Migliaccio announces the release of ‘1st Generation Rich’

ALBUQUERQUE, N.M., Sept. 30, 2020 (GLOBE NEWSWIRE) — Mark J. Migliaccio wanted to open the eyes of anyone who always wanted to start a business or invest in real estate but never knew how to get started. He wants to show that there are many more options to the daily grind and “working in a job you dislike with people you would never invite to one of your barbecues.” It is for these reasons that he writes “1st Generation Rich” (published by Archway Publishing), a book about how to build a money-generating machine that pays all your bills, become 1st Generation Rich while having fun doing it.


In this guide to building wealth, Migliaccio explores how to build a business that puts one in control of his/her valuable time, master the art of making money by investing in real estate and view money as a valuable tool instead of being taboo. He explains that by creating more options, one will have more freedoms.


“Technology has changed just about everything yet these basic principals have been the building blocks for any start up or investments for thousands of years,” Migliaccio points out. “I’m not trying to reinvent the wheel I just found a different way to become rich by taking the path that was less traveled. This journey is my personal story on how I was able to build a successful business and invest in real estate with a learning disability, no education, no money, no help and no safety net if I was to fail.”


When asked what he wants readers to take away from his writing of the book, Migliaccio replies, “This entire book from the 1st word to the last word was written with one goal in mind,